title: Acute myeloid leukaemia in children.
abstract: Acute myeloid leukaemia (AML) is characterized by a block in differentiation and an unregulated proliferation of myeloid progenitor cells. While the cause of AML in children is unknown, risk factors that have been identified include exposure to toxins such as ethanol, pesticides and dietary topoisomerase II inhibitors, prior chemotherapy with alkylating agents or topoisomerase II inhibitors, constitutional disorders such as Down's syndrome and type I neurofibromatosis, and haematopoietic failure syndromes such as Fanconi anaemia and severe congenital neutropenia. With intensified chemotherapy including high-dose Ara-C, followed in many cases by bone marrow transplantation, and with improvements in supportive care, current survival rates approach 50%. Future advances in paediatric AML will include better risk stratification to determine optimal treatment and targeted cytotoxic therapy.
authors.affiliation: The University of Pennsylvania School of Medicine, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA, 19104, USA.
authors.forename: P B
authors.initials: PB
authors.lastname: Langmuir
authors.forename: R
authors.initials: R
authors.lastname: Aplenc
authors.forename: B J
authors.initials: BJ
authors.lastname: Lange
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D012307:Risk Factors; D016896:Treatment Outcome